title: Phenotype/endotype-driven therapy in COPD: potential economic implications.
authors: Sabina A
authors: SA
authors: Antoniu
mesh_terms: D000631:Aminopyridines / Q000191:economics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000191:economics* / Q000627:therapeutic use*; D001549:Benzamides / Q000191:economics / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003521:Cyclopropanes / Q000191:economics / Q000627:therapeutic use; D018450:Disease Progression; D016527:Drug Costs; D005541:Forced Expiratory Volume; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000503:physiopathology; D018579:Patient Selection; D010641:Phenotype; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics* / Q000503:physiopathology; D011656:Pulmonary Emphysema / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D000893:Anti-Inflammatory Agents; D001549:Benzamides; D001993:Bronchodilator Agents; D003521:Cyclopropanes; C424423:Roflumilast